HUP0100284A2 - Aktivált protein C készítmények - Google Patents

Aktivált protein C készítmények

Info

Publication number
HUP0100284A2
HUP0100284A2 HU0100284A HUP0100284A HUP0100284A2 HU P0100284 A2 HUP0100284 A2 HU P0100284A2 HU 0100284 A HU0100284 A HU 0100284A HU P0100284 A HUP0100284 A HU P0100284A HU P0100284 A2 HUP0100284 A2 HU P0100284A2
Authority
HU
Hungary
Prior art keywords
activated protein
formulations
preparations
stable
during storage
Prior art date
Application number
HU0100284A
Other languages
English (en)
Inventor
Andrew David Carlson
Theodore Arsay Sheliga
Original Assignee
Eli Lilly And Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Co. filed Critical Eli Lilly And Co.
Publication of HUP0100284A2 publication Critical patent/HUP0100284A2/hu
Publication of HUP0100284A3 publication Critical patent/HUP0100284A3/hu
Publication of HU224826B1 publication Critical patent/HU224826B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Abstract

A találmány aktivált protein C-t tartalmazó gyógyszerkészítményekkelfoglalkozik, melyek az aktivált protein C mellett szacharózt, nátrium-kloridot és nátrium-citrát puffert, pH = 5,5-6,5 is tartalmaznak. Ajelen találmány szerinti aktivált protein C készítmények az eddigiaktivált protein C készítményeknél stabilabbak és a tárolás folyamánkevesebb degradációs termék jelenléte mutatható ki. Ó
HU0100284A 1997-04-28 1998-04-24 Activated protein c formulations HU224826B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4525597P 1997-04-28 1997-04-28
PCT/US1998/008386 WO1998048818A1 (en) 1997-04-28 1998-04-24 Activated protein c formulations

Publications (3)

Publication Number Publication Date
HUP0100284A2 true HUP0100284A2 (hu) 2001-06-28
HUP0100284A3 HUP0100284A3 (en) 2003-08-28
HU224826B1 HU224826B1 (en) 2006-02-28

Family

ID=21936854

Family Applications (2)

Application Number Title Priority Date Filing Date
HU0003401A HUP0003401A3 (en) 1997-04-28 1998-04-24 Improved methods for processing activated protein c
HU0100284A HU224826B1 (en) 1997-04-28 1998-04-24 Activated protein c formulations

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HU0003401A HUP0003401A3 (en) 1997-04-28 1998-04-24 Improved methods for processing activated protein c

Country Status (35)

Country Link
US (4) US6159468A (hu)
EP (2) EP0875252B1 (hu)
JP (2) JP4383546B2 (hu)
KR (2) KR100564189B1 (hu)
CN (2) CN1227025C (hu)
AR (2) AR015598A1 (hu)
AT (1) ATE285788T1 (hu)
AU (2) AU740753C (hu)
BR (2) BR9809292A (hu)
CA (2) CA2287267C (hu)
CO (2) CO4940438A1 (hu)
CZ (1) CZ298429B6 (hu)
DE (1) DE69828330T2 (hu)
DK (1) DK0875252T3 (hu)
EA (2) EA004881B1 (hu)
EG (1) EG23685A (hu)
ES (1) ES2234072T3 (hu)
HK (1) HK1016472A1 (hu)
HU (2) HUP0003401A3 (hu)
ID (2) ID23172A (hu)
IL (2) IL132502A0 (hu)
IN (2) IN187157B (hu)
MY (2) MY120984A (hu)
NO (2) NO995134L (hu)
NZ (2) NZ337828A (hu)
PE (2) PE86299A1 (hu)
PL (2) PL195090B1 (hu)
PT (1) PT875252E (hu)
SI (1) SI0875252T1 (hu)
SV (2) SV1998000050A (hu)
TR (2) TR199902529T2 (hu)
TW (2) TW585871B (hu)
UA (2) UA73071C2 (hu)
WO (2) WO1998048818A1 (hu)
ZA (2) ZA983496B (hu)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ337828A (en) 1997-04-28 2001-06-29 Lilly Co Eli Activated protein C formulations having a bulking agent and a salt
US6630137B1 (en) * 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
ATE320263T1 (de) * 1998-11-13 2006-04-15 Lilly Co Eli Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
BR9915460A (pt) * 1998-11-20 2001-07-17 Lilly Co Eli Método de tratamento de febre hemorrágica virótica
DE69905489T2 (de) * 1998-11-23 2003-09-11 Lilly Co Eli Protein c zur behandlung von sichelzellanämie und thalassämie
IL142249A0 (en) * 1998-12-10 2002-03-10 Lilly Co Eli Method of treating thrombocytopenic purpura and hemolytic uremic syndrome
US6758938B1 (en) * 1999-08-31 2004-07-06 Micron Technology, Inc. Delivery of dissolved ozone
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
AU2001262939A1 (en) * 2000-05-24 2001-12-03 Eli Lilly And Company Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
EP1998266A3 (en) 2001-02-19 2009-02-11 Merck Patent GmbH Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity
US7101982B2 (en) * 2001-03-30 2006-09-05 Immunex Corporation Control of ph transitions during chromatography
EP1417055A4 (en) * 2001-07-19 2007-09-26 Dmi Biosciences Inc USE OF COPPER CHELATORS TO PREVENT THE INACTIVATION OF PROTEIN C
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
US6838432B2 (en) 2001-09-19 2005-01-04 Oklahoma Medical Research Foundation Treatment of sepsis with TAFI
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
EA200400548A1 (ru) 2001-10-15 2005-06-30 Чирон Корпорейшн Лечение тяжёлой пневмонии путём введения ингибитора пути тканевого фактора (tfpi)
BR0215216A (pt) 2001-12-21 2004-11-16 Novo Nordisk Healthcare Ag Composição aquosa lìquida, método para preparar uma composição aquosa lìquida de um polipeptìdeo de fator vii, uso de uma composição aquosa lìquida, e, método para o tratamento de uma sìndrome de resposta ao fator vii
JP2005528351A (ja) * 2002-03-08 2005-09-22 イーライ・リリー・アンド・カンパニー 活性化プロテインｃ製剤
ES2523655T5 (es) 2002-06-21 2018-04-23 Novo Nordisk Health Care Ag Composiciones sólidas estabilizadas de polipéptidos del Factor VIIa
NZ539811A (en) * 2002-10-29 2008-08-29 Alza Corp Solid-state polypeptide particles that facilitate the loading of an implant delivery system with a concentration of stabilised, therapeutic polypeptide sufficiently high to enable delivery of therapeutic doses of the polypeptide over an extended period of time
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
ATE547114T1 (de) * 2003-06-25 2012-03-15 Novo Nordisk Healthcare Ag Flüssige zusammensetzungen von factor vii polypeptiden
CN101426520A (zh) * 2004-03-17 2009-05-06 诺华疫苗和诊断公司 通过给予组织因子途径抑制剂（tfpi）治疗社区获得性重症肺炎
JP2008507561A (ja) * 2004-07-23 2008-03-13 ザ ユニバーシティ オブ ロチェスター 活性化プロテインｃによる、脳内のプラスミノゲン活性化因子の不都合な作用の阻害
CA2612859A1 (en) * 2005-06-23 2006-12-28 The University Of British Columbia Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
WO2007139553A1 (en) * 2006-05-31 2007-12-06 Genzyme Corporation Use of polysaccharides for promotion of enzymatic activity
EP2041338A4 (en) * 2006-06-09 2009-09-30 Univ British Columbia INTERFERON GAMMA POLYMORPHISMS AS INDICATORS OF PATIENT RESULTS IN FATIGUE PATIENTS
WO2008107908A1 (en) * 2007-03-05 2008-09-12 Cadila Healthcare Limited Compositions comprising peg- interferon alpha conjugates and raffinose as cryoprotectant
NZ598881A (en) * 2007-03-29 2013-11-29 Abbvie Inc Crystalline anti-human il-12 antibodies
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CA2707483A1 (en) * 2007-11-30 2009-06-11 Wolfgang Fraunhofer Protein formulations and methods of making same
WO2009089620A1 (en) * 2008-01-15 2009-07-23 The Universityof British Columbia Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
WO2010062896A1 (en) * 2008-11-28 2010-06-03 Abbott Laboratories Stable antibody compositions and methods for stabilizing same
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP2834635A4 (en) 2012-04-03 2015-09-02 Smiths Medical Asd Inc COMPOSITIONS WITH A HEPARINE ACCUMULATIVE AND METHOD THEREFOR
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
ES2676422T3 (es) 2012-07-04 2018-07-19 Zz Biotech Llc Proteína C activada para su uso en el tratamiento de trastornos inflamatorios de la piel
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CN106573040B (zh) 2014-04-16 2021-07-06 Zz生物技术有限责任公司 治疗异常皮肤瘢痕形成
US11058750B2 (en) 2015-12-03 2021-07-13 Mor Research Applications Ltd. Compositions and methods for treatment of ocular diseases
PT3463308T (pt) * 2016-06-01 2022-03-11 Servier Ip Uk Ltd Formulações de óxido de polialquileno asparaginase e métodos de fabrico e utilização do mesmo
CN108159399B (zh) * 2017-12-29 2020-07-24 华中科技大学同济医学院附属同济医院 一种凝血蛋白酶aPC在防治糖尿病心肌病药物中的应用
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4849403A (en) * 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
AT399095B (de) * 1986-03-27 1995-03-27 Vukovich Thomas Dr Verfahren zur auftrennung von proteinen mittels gradientenelution und vorrichtung zur durchführung des verfahrens
US5175087A (en) * 1987-07-06 1992-12-29 Biopool International, Inc. Method of performing tissue plasminogen activator assay
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
JPH01226900A (ja) * 1988-03-08 1989-09-11 Green Cross Corp:The プロテインｃの精製方法
DE3823519A1 (de) * 1988-07-12 1990-01-18 Basf Ag Verfahren zur reinigung von aktiviertem protein c
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
JPH05506354A (ja) * 1990-02-09 1993-09-22 ザイモジェネティクス，インコーポレイティド 端が切り取られた軽鎖を有する活性プロテインｃ
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5040862A (en) 1990-05-07 1991-08-20 Corning Incorporated Method of trimming optical power
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
US5413732A (en) * 1991-08-19 1995-05-09 Abaxis, Inc. Reagent compositions for analytical testing
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5395923A (en) * 1993-02-23 1995-03-07 Haemacure-Biotech, Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out"
JP2886061B2 (ja) * 1993-10-29 1999-04-26 財団法人化学及血清療法研究所 プロテインｃもしくは活性化プロテインｃの安定化方法及び安定化組成物
JP3043558B2 (ja) * 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
JPH07165605A (ja) * 1993-12-16 1995-06-27 Teijin Ltd 活性化プロテインｃバイアル
NZ270271A (en) * 1994-01-05 1996-07-26 Lilly Co Eli Minimizing protein c degradation
JPH08301786A (ja) * 1995-05-11 1996-11-19 Mochida Pharmaceut Co Ltd 吸収性骨疾患予防・治療剤
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
NZ337828A (en) * 1997-04-28 2001-06-29 Lilly Co Eli Activated protein C formulations having a bulking agent and a salt
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
IL132325A0 (en) 2001-03-19
HK1016472A1 (en) 1999-11-05
PL195090B1 (pl) 2007-08-31
EP0875252A2 (en) 1998-11-04
ZA983496B (en) 1999-10-25
PL336420A1 (en) 2000-06-19
JP4383547B2 (ja) 2009-12-16
UA55448C2 (uk) 2003-04-15
UA73071C2 (en) 2005-06-15
US6395270B1 (en) 2002-05-28
CZ381099A3 (cs) 2000-03-15
CN1227025C (zh) 2005-11-16
DK0875252T3 (da) 2005-04-25
PE86299A1 (es) 1999-09-17
HUP0003401A2 (hu) 2001-02-28
KR100564189B1 (ko) 2006-03-27
NO995198L (no) 1999-10-25
CA2288143C (en) 2012-08-21
CA2287267C (en) 2006-08-15
JP4383546B2 (ja) 2009-12-16
PE84799A1 (es) 1999-09-16
BR9809304A (pt) 2000-10-17
AU7161898A (en) 1998-11-24
EG23685A (en) 2007-05-09
IN187157B (hu) 2002-02-16
CO4950523A1 (es) 2000-09-01
NO995134D0 (no) 1999-10-21
EA004881B1 (ru) 2004-08-26
AU740753C (en) 2002-10-10
WO1998048818A1 (en) 1998-11-05
CA2287267A1 (en) 1998-11-05
EP0875252A3 (en) 2000-07-26
DE69828330T2 (de) 2005-10-13
EA199900979A1 (ru) 2000-06-26
AR015598A1 (es) 2001-05-16
KR20010020325A (ko) 2001-03-15
PT875252E (pt) 2005-03-31
CN1261280A (zh) 2000-07-26
EA002149B1 (ru) 2001-12-24
TWI242443B (en) 2005-11-01
HU224826B1 (en) 2006-02-28
EP0875252B1 (en) 2004-12-29
EA199900980A1 (ru) 2000-04-24
IL132502A0 (en) 2001-03-19
WO1998048822A1 (en) 1998-11-05
CZ298429B6 (cs) 2007-10-03
KR20010020242A (ko) 2001-03-15
KR100450856B1 (ko) 2004-10-02
IL132325A (en) 2005-07-25
AU743531B2 (en) 2002-01-31
HUP0100284A3 (en) 2003-08-28
EP0875563A3 (en) 2000-08-02
US6159468A (en) 2000-12-12
SV1998000051A (es) 1998-12-11
AU7258998A (en) 1998-11-24
CO4940438A1 (es) 2000-07-24
NO995134L (no) 1999-12-21
ATE285788T1 (de) 2005-01-15
NZ337828A (en) 2001-06-29
TR199902529T2 (xx) 2000-02-21
NO995198D0 (no) 1999-10-25
HUP0003401A3 (en) 2003-01-28
ZA983497B (en) 1999-10-25
MY120984A (en) 2005-12-30
AR012010A1 (es) 2000-09-13
TR199902631T2 (xx) 2000-01-21
PL195642B1 (pl) 2007-10-31
JP2001524111A (ja) 2001-11-27
MY118591A (en) 2004-12-31
SI0875252T1 (en) 2005-06-30
IN183798B (hu) 2000-04-15
PL336889A1 (en) 2000-07-17
US6436397B1 (en) 2002-08-20
ID23172A (id) 2000-03-23
SV1998000050A (es) 1999-01-13
BR9809304B1 (pt) 2011-02-08
BR9809292A (pt) 2000-07-04
TW585871B (en) 2004-05-01
JP2001527543A (ja) 2001-12-25
AU740753B2 (en) 2001-11-15
CA2288143A1 (en) 1998-11-05
CN1254284A (zh) 2000-05-24
EP0875563A2 (en) 1998-11-04
DE69828330D1 (de) 2005-02-03
NZ500346A (en) 2001-08-31
CN1235638C (zh) 2006-01-11
ES2234072T3 (es) 2005-06-16
US6162629A (en) 2000-12-19
ID22933A (id) 1999-12-16

Similar Documents

Publication Publication Date Title
HUP0100284A2 (hu) Aktivált protein C készítmények
CA2113995A1 (en) Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins
FR2581877B1 (fr) Conjugue constitue d'une adhesine de paroi de s. mutans, de nature proteique et d'un polysaccharide de s. mutans, sa preparation et son utilisation notamment dans des vaccins anti-caries
LV10178A (lv) Fiziologiski saderigu glabajot stabilu cilveka olbaltumvielu preparatu iegusanas panemiens
DK155318C (da) Indoxyl- og thioindoxyl-aminosyreestere og -peptidestere, diagnostisk middel indeholdende dem, og deres anvendelse i diagnostiske midler
BG103977A (en) Low molecular rotamase enzymic activity inhibitors
HUP0000737A2 (hu) Hialuronsav mikrorészecskékbe foglalt hatóanyagokat tartalmazó nyújtott hatóanyagleadású készítmény
DE69620877D1 (de) Arzneimittelformulierungen für il-12
CA2257133A1 (en) Human dnase i hyperactive variants
ES2042693T5 (es) Formulaciones de proteinas plasmaticas y recombinantes en medios de baja potencia ionica.
DK0984982T3 (da) LH-RH-peptidanaloger, anvendelse deraf og farmaceutiske præparater indeholdende dem
ES2053676T3 (es) Formulacion de proteinas plasmaticas y recombinantes en medios de fuerza ionica elevada.
YU53098A (sh) Preparat koncentrovanog antitela
DE69331739D1 (de) Neuartige pharmazeutische verwendungen von krill-enzymen
HUP9701437A3 (en) Use of complex lipides as stabilizing additives in pharmaceutical compositions containing digestive enzymes, pharmaceutical compns. and kits
CA2279349A1 (en) Ascorbate-stabilized radiopharmaceutical method and composition
RU94041224A (ru) Пептиды с органозащитной активностью, фармацевтическая композиция на их основе и их применение в терапии
HUP9900506A2 (hu) Protrombinszármazékok
IT1270618B (it) Proteine ad attivita' antitumorale
MA21385A1 (fr) Derives d'alcadienes, leurs preparations, les produits les contenant et produits intermediaires.
ITMI911853A0 (it) Sale del diclofenac, metodo di preparazione e composizioni farmaceutiche che lo contengono
DE3560313D1 (en) Improvements in or relating to anticonvulsant agents
MA26447A1 (fr) Analogues peptidiques de la lh-rh, leurs utilisations et compositions pharmaceutiques en contenant
IT1235336B (it) Sale di trometammina di i-metil-beta-osso-alfa-(fenilcarbammoil)-2- pirrolpropionitrile, composizione che lo contiene e procedimento di preparazione ed applicazione
HUP0000812A2 (hu) Myelin bázikus fehérje peptid-fragmentumai az azokat tartalmazó gyógyszerkészítmények és felhasználásuk a sclerosis multiplex kezelésére

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees